Retension prices upsized IPO at $12, raising $45M for hypertension drug
What's the deal? Retension Pharmaceuticals has priced its upsized initial public offering at $12 per share, raising $45 million before expenses. Trading begins October 9, 2026, on Nasdaq under the ticker RTSN.
What's the endgame? The company develops treatments for hypertension and cardiovascular diseases. Its lead candidate is RTN-001, a hypertension drug.
Why now? Proceeds will fund the completion of Phase 2b trials and advance RTN-001 into Phase 3 — the capital-intensive late stage of drug development that often pushes biotech firms toward public markets.
The signal: Retension's debut lands in a mixed health sector. Of 128 US health-sector stocks tracked by Pluang on October 9, 77 fell and 51 rose, underscoring the pressure on biotech names as the company courts public investors.
Read more: pluang.com
Image credit: medisave
